Outcomes-based market access agreements
Resources for Canadian stakeholders
Outcomes-based market access agreements: Resources for Canadian stakeholders
The RWE & OBA Working Group
Since 2019, the RWE & OBA Working Group has brought together organizations inspired by the opportunity for real-world evidence (RWE) generation to support outcomes-based agreements (OBAs) in Canada. Together, we’re developing and implementing OBA market access models that support timely and equitable patient access to novel therapies, and value-based healthcare for all.
Current working group members include:
Research and Publications
Peer-Reviewed Article: Financial Characteristics of Outcomes-Based Agreements: What do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?
This study sought to gain insight into the financial characteristics of outcomes-based agreements (OBAs) considered most suitable to Canadian public payers and pharmaceutical manufacturers, and the rationale for their preferences. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. Advance online publication date: Dec. 2023
Poster: Leveraging real-world data from the private payer prior authorization process to operationalize outcomes-based agreements in Canada
This study sought to evaluate if existing prior authorization processes used by private payers could be leveraged to support outcomes-based managed access agreements. Presented at the Canadian Association for Population Therapeutics Conference on October 23, 2023, Toronto, Canada.
CADTH Symposium Panel Presentation: Can Canada’s multi-payer system be inspired by international approaches for managing evidence uncertainty related to value while providing patients with timely access to life-saving therapies?
In this panel session, healthcare leaders Sylvie Bouchard, INESSS, Martine Elias, Myeloma Canada, Carole Chambers, Alberta Health Services, and Thomas Strong, NICE, provided their insights on potential Canadian solutions. Presented at the CADTH Symposium, May 18, 2023.
2022 RWE & OBA Working Group Executive Summary Report
The working group had two primary areas of research in 2022: Investigating the feasibility and current infrastructure readiness to collect real-world data to support an outcomes-based agreement in Canada, focusing on the existing prior authorization processes used by private payers, and investigating the needs of payers and manufacturers regarding OBA financial adjudication. Publication date: Dec. 2022.
Peer-Reviewed Article: Building Infrastructure for Outcomes-Based Agreements in Canada
Outcomes-based agreements (OBAs) have the potential to provide more timely patient access to novel therapies, although they are not suitable for every new medication or reimbursement scenario. The authors of this paper studied how to operationalize an OBA in oncology by leveraging existing real-world data (RWD) infrastructure in the province of Alberta. Publication date: Dec. 13, 2022.
2021 RWE & OBA Working Group Executive Summary Report
By building on the research conducted and tools developed to support OBA implementation by the working group in 2019 and 2020, in 2021 there was a continued focus on research and analysis to bring clarity on the opportunity for OBAs in Canada, while developing expertise and knowledge in key areas to ensure readiness for OBA implementation. Publication date: Dec. 2021.
Survey Results & Poster: Canadian Outcomes-Based Agreements Experience and Perceptions
In 2021 the RWE & OBA Working Group conducted research on outcomes-based agreements to understand Canadian stakeholders’ current positions and knowledge of OBAs, current experience with OBAs, and future plans for OBAs.
A poster with key insights from the survey was presented at the Canadian Association for Population Therapeutics Virtual Conference, October 25, 2021.
CADTH Symposium Panel Presentation: Building infrastructure to support outcomes-based agreements in Canada: Can an outcomes-based agreement in oncology be operationalized using administrative health data?
Presented at the CADTH Symposium, Nov. 3, 2021.
2020 RWE & OBA Working Group Executive Summary Report
In 2020, the working group had two primary areas of research, including: investigating the value of an outcomes-based agreement by creating an Outcomes-Based Agreement Decision Modelling Tool (developed in collaboration with Affiliated Working Group SME Collaborator EVERSANA) and; further investigating the patient support program data and infrastructure opportunity for RWD generation and usage in OBAs, by conducting a Canadian Patient Support Program Data Capabilities Survey. Publication date: Dec. 2020.
Poster: Can Canada’s PSP infrastructure support the collection of RWE for OBAs
Presented at the Canadian Association for Population Therapeutics Virtual Conference, October 26, 2020.
Video: Can Canada’s patient support program infrastructure support the collection of RWD for use in OBAs?
Presented at the Canadian Association for Population Therapeutics Virtual Conference, October 26, 2020.
Survey Results: Canadian PSP Data Capabilities
This survey looks at the baseline state of PSP data, PSP data capabilities, and future plans for PSP data collection in Canada. Publication date: Oct. 15, 2020.
2019 RWE & OBA Working Group Executive Summary Report
In 2019, the working group’s primary focus was on research and analysis to bring clarity on the opportunity for OBA in Canada, and to develop a framework for OBA implementation in Canada. Publication date: Nov. 2019.
RWE to Support OBA in Canada: A Case Study Using PSP Data
This case study, on the use of the PSP infrastructure to collect data on a drug with the intent of establishing an outcomes-based agreement at product launch, was presented as a panel discussion at the 2019 Canadian Association for Population Therapeutics Conference, October 2019.